Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 149,842	$ 92,117
Accounts receivable	2,828	201
Prepaid expenses and other current assets	5,518	4,884
Research and development incentives receivable	5,970	6,944
Total current assets	164,158	104,146
Property and equipment, net	2,039	2,292
Operating lease right-of-use assets	1,459	2,056
Other assets	2,403	1,700
Total assets	170,059	110,194
Current liabilities:
Accounts payable	2,056	1,949
Accrued expenses and other current liabilities	7,798	6,144
Deferred revenue, current portion	7,193	728
Total current liabilities	17,047	8,821
Long-term debt	14,427
Operating lease liabilities	645	1,251
Deferred revenue, net of current portion	26,082	4,929
Other long-term liabilities	2,307	1,995
Total liabilities	60,508	16,996
Commitments and contingencies (Note 13)
Shareholders’ equity:
Ordinary shares, £0.01 nominal value; 31,995,653 shares authorized at September 30, 2020 and December 31, 2019; 20,935,853 and 17,993,701 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	264	227
Additional paid-in capital	246,391	195,056
Accumulated other comprehensive loss	(2,977)	(1,535)
Accumulated deficit	(134,127)	(100,550)
Total shareholders’ equity	109,551	93,198
Total liabilities and shareholders’ equity	$ 170,059	$ 110,194